Hoth Therapeutics Inc. has entered into an exclusive patent license agreement with the U.S. Department of Veterans Affairs (VA), providing Hoth with exclusive rights to a jointly owned patent portfolio co-developed by the VA and Emory University.

Xentria Inc. has entered into an exclusive license agreement with New York University (NYU) securing Xentria exclusive rights related to the development of a potential disease-modifying therapeutic for cardiovascular disease.

Bioarctic AB has entered into a global exclusive license agreement with Bristol Myers Squibb Co. for Bioarctic’s pyroglutamate-amyloid-β (Aβ) antibody program.